4 news items
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
BCLI
14 Jun 24
(debamestrocel, MSC-NTF) revealed positive clinical responses with respect to slowing of ALS disease progression (primary endpoint). However the PIII trial cohort
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
BCLI
14 Jun 24
-NTF) revealed positive clinical responses with respect to slowing of ALS disease progression (primary endpoint). However the PIII trial cohort
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
BCLI
16 Apr 24
and Chief Medical Officer, Dr. Dagher's responsibilities will include overseeing the planned Phase
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
BCLI
1 Apr 24
review, and the Company is expecting to have a response from the US FDA very soon as we approach the 45-day SPA review cycle
- Prev
- 1
- Next